Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 8.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 399,875 shares of the medical research company’s stock after selling 39,231 shares during the quarter. Vontobel Holding Ltd. owned about 0.07% of Edwards Lifesciences worth $29,603,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the business. Bowman & Co S.C. lifted its holdings in shares of Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after buying an additional 148 shares during the period. Mount Yale Investment Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 1.9% in the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after buying an additional 162 shares during the period. JFS Wealth Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares during the period. Seascape Capital Management lifted its holdings in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock valued at $2,177,000 after buying an additional 174 shares during the period. Finally, Cooper Financial Group lifted its holdings in shares of Edwards Lifesciences by 2.8% in the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after buying an additional 175 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EW has been the subject of several research reports. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $82.00 to $90.00 in a report on Monday, December 16th. JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Barclays lifted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $79.95.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,489 shares of company stock valued at $2,002,829. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $76.23 on Friday. The business has a fifty day simple moving average of $72.58 and a 200-day simple moving average of $69.41. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $44.96 billion, a P/E ratio of 11.00, a P/E/G ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.